1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia - Pipeline Review, H2 2020, provides an overview of the Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 6, 61, 71, 3, 10, 67, 8 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 15, 13 and 7 molecules, respectively.
Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionChronic Lymphocytic Leukemia - Overview
Chronic Lymphocytic Leukemia - Therapeutics Development
Chronic Lymphocytic Leukemia - Therapeutics Assessment
Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development
Chronic Lymphocytic Leukemia - Drug Profiles
Chronic Lymphocytic Leukemia - Dormant Projects
Chronic Lymphocytic Leukemia - Discontinued Products
Chronic Lymphocytic Leukemia - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Therapeutics Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acepodia Biotech Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acerta Pharma BV, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Actinium Pharmaceuticals Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics SA, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by AgenTus Therapeutics Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Agenus Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by AI Therapeutics Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Anew Oncology Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Apotex Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprea Therapeutics Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ascenta Therapeutics Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ascentage Pharma Group International, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by AVM Biotechnology LLC, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bantam Pharmaceutical LLC, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Beijing GD Initiative Cell Therapy Technology Co Ltd, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by BendaRx Corp, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bio-Path Holdings Inc, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by BioIntegrator Ltd, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Pipeline by BioNTech SE, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2020
- Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4SC AG
- AbbVie Inc
- ABL Bio Inc
- ACEA Therapeutics Inc
- Acepodia Biotech Inc
- Acerta Pharma BV
- Actinium Pharmaceuticals Inc
- ADC Therapeutics SA
- Adlai Nortye Biopharma Co Ltd
- Aeglea BioTherapeutics Inc
- AgenTus Therapeutics Inc
- Agenus Inc
- AI Therapeutics Inc
- Anew Oncology Inc
- Apotex Inc
- Aprea Therapeutics Inc
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- AstraZeneca Plc
- AVM Biotechnology LLC
- Bantam Pharmaceutical LLC
- Bayer AG
- BeiGene Ltd
- Beijing GD Initiative Cell Therapy Technology Co Ltd
- Beijing Mabworks Biotech Co Ltd
